In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer

References

• FornerALlovetJMBruixJHepatocellular carcinomaLancet201237998221245125522353262
   PubMed Web of Science ®Google Scholar
• HuynhHMolecularly targeted therapy in hepatocellular carcinomaBiochem Pharmacol201080555056020371362
   PubMed Web of Science ®Google Scholar
• BertinoGHepatocellular carcinoma: present and futureChin Clin Oncol2012111425842072
   PubMedGoogle Scholar
• DiFrancesco C [webpage on the Internet]FDA Approves Nexavar for Patients with Inoperable Liver Cancer2007 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109030.htmAccessed April 14, 2016
   Google Scholar
• BensonAB3rdAbramsTABen-JosefENCCN clinical practice guidelines in oncology: hepatobiliary cancersJ Natl Compr Canc Netw20097435039119406039
   PubMed Web of Science ®Google Scholar
• LlovetJMDi BisceglieAMBruixJDesign and endpoints of clinical trials in hepatocellular carcinomaJ Natl Cancer Inst20081001069871118477802
   PubMedGoogle Scholar
• LeoniSPiscagliaFSerioIAdherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology GroupDig Liver Dis201446654955524630947
   PubMedGoogle Scholar
• LlovetJMBruixJMolecular targeted therapies in hepatocellular carcinomaHepatology20084841312132718821591
   PubMed Web of Science ®Google Scholar
• WilhelmSCarterCLynchMDiscovery and development of sorafenib: a multikinase inhibitor for treating cancerNat Rev Drug Discov200651083584417016424
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
   PubMed Web of Science ®Google Scholar
• ChengALKangYKChenZEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialLancet Oncol2009101253419095497
   PubMed Web of Science ®Google Scholar
• MancusoAAiroldiAViganoRPinzelloGFatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantationDig Liver Dis201143975421641889
   PubMedGoogle Scholar
• ZhangZNiuBChenJThe use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancerBiomaterials201435154565457224602567
   PubMed Web of Science ®Google Scholar
• LiuYFengLLiuTMultifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancerNanoscale2014663231324224500240
   PubMed Web of Science ®Google Scholar
• Waknine Y [webpage on the Internet]FDA Approvals: Nascobal Nasal Spray, PTC 124, Tocosol Paclitaxel2005 Available from: http://www.medscape.com/viewarticle/498694Accessed January 12, 2016
   Google Scholar
• ChangEHHarfordJBEatonMANanomedicine: past, present and future – a global perspectiveBiochem Biophys Res Commun2015468351151726518648
   PubMed Web of Science ®Google Scholar
• CaiLTShengZHAdvances in cancer nanomedicineCancer Biol Med201512314114226487958
   PubMedGoogle Scholar
• DuncanRGasparRNanomedicine(s) under the microscopeMol Pharm2011862101214121974749
   PubMed Web of Science ®Google Scholar
• WickiAWitzigmannDBalasubramanianVHuwylerJNanomedicine in cancer therapy: challenges, opportunities, and clinical applicationsJ Control Release201520013815725545217
   PubMed Web of Science ®Google Scholar
• XuXHoWZhangXBertrandNFarokhzadOCancer nanomedicine: from targeted delivery to combination therapyTrends Mol Med201521422323225656384
   PubMed Web of Science ®Google Scholar
• BarrattGBretagneSOptimizing efficacy of Amphotericin B through nanomodificationInt J Nanomedicine20072330131318019830
   PubMed Web of Science ®Google Scholar
• BarenholzYDoxil(R) – the first FDA-approved nano-drug: lessons learnedJ Control Release2012160211713422484195
   PubMed Web of Science ®Google Scholar
• WangXQFanJMLiuYOZhaoBJiaZRZhangQBioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to ratInt J Pharm20114191–233934621843612
   PubMed Web of Science ®Google Scholar
• Lin TsTGaoDYLiuYCDevelopment and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosisJ Control Release2016221627026551344
   PubMedGoogle Scholar
• ShenJSunHMengQSimultaneous inhibition of tumor growth and angiogenesis for resistant hepatocellular carcinoma by co-delivery of sorafenib and survivin small hairpin RNAMol Pharm201411103342335124495194
   PubMed Web of Science ®Google Scholar
• CraparoEFSardoCSerioRGalactosylated polymeric carriers for liver targeting of sorafenibInt J Pharm20144661–217218024607205
   PubMedGoogle Scholar
• YaoYSuZLiangYZhangNpH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-deliveryInt J Nanomedicine2015106185619726491291
   PubMed Web of Science ®Google Scholar
• DanhierFUcakarBVanderhaegenMLBrewsterMEArienTPreatVNanosuspension for the delivery of a poorly soluble anti-cancer kinase inhibitorEur J Pharm Biopharm201488125226024859391
   PubMedGoogle Scholar
• WangLLiuZLiuDLiuCJuanZZhangNDocetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activityInt J Pharm20114131–219420121540085
   PubMed Web of Science ®Google Scholar
• ZhangJLiMLiuZWangLLiuYZhangNPreclinical studies of N(3)-O-toluyl-fluorouracil-loaded lipid-based nanosuspensions in H(2)(2)-bearing miceInt J Nanomedicine201492741275124920908
   PubMedGoogle Scholar
• YuWLiuCLiuYZhangNXuWMannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophagesPharm Res20102781584159620422265
   PubMed Web of Science ®Google Scholar
• SuZLiangYYaoYPolymeric complex micelles based on the double-hydrazone linkage and dual drug-loading strategy for pH-sensitive docetaxel deliveryJ Mater Chem B2016411221133
   PubMed Web of Science ®Google Scholar
• WangLLiMZhangNFolate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapyInt J Nanomedicine201273281329422802688
   PubMed Web of Science ®Google Scholar
• WangMLiuTHanLGaoWYangSZhangNFunctionalized O-carboxymethyl-chitosan/polyethylenimine based novel dual pH-responsive nanocarriers for controlled co-delivery of DOX and genesPolym Chem201561733243335
   Web of Science ®Google Scholar
• YangCLiuSQVenkataramanSStructure-directing star-shaped block copolymers: supramolecular vesicles for the delivery of anticancer drugsJ Control Release20152089310525813888
   PubMed Web of Science ®Google Scholar
• AttiaABYangCTanJPThe effect of kinetic stability on biodistribution and anti-tumor efficacy of drug-loaded biodegradable polymeric micellesBiomaterials201334123132314023380357
   PubMedGoogle Scholar
• BotellaPAbasoloIFernandezYSurface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluationJ Control Release2011156224625721756949
   PubMed Web of Science ®Google Scholar
• ZarrabiAVossoughiMPaclitaxel/β-CD-g-PG inclusion complex: an insight into complexation thermodynamics and guest solubilityJ Mol Liq2015208145150
   Web of Science ®Google Scholar
• AliHSMYorkPAliAMABlagdenNHydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet millingJ Control Release2011149217518120946923
   PubMed Web of Science ®Google Scholar
• LiuFLiMLiuCTumor-specific delivery and therapy by double-targeted DTX-CMCS-PEG-NGR conjugatesPharm Res201431247548824043295
   PubMedGoogle Scholar
• ZhangHZhangFMYanSJPreparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticlesInt J Nanomedicine201272901291022787390
   PubMed Web of Science ®Google Scholar
• RewatkarPVPartonRGParekhHSParatMOAre caveolae a cellular entry route for non-viral therapeutic delivery systems?Adv Drug Deliv Rev2015919210825579057
   PubMedGoogle Scholar
• GaoLZhangDChenMStudies on pharmacokinetics and tissue distribution of oridonin nanosuspensionsInt J Pharm20083551–232132718242896
   PubMed Web of Science ®Google Scholar
• PetersKLeitzkeSDiederichsJEPreparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infectionJ Antimicrob Chemother2000451778310629016
   PubMed Web of Science ®Google Scholar
• WangLLiMZhangNFolate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapyInt J Pharm2012732813293
   Google Scholar
• HollisCPWeissHLLeggasMEversBMGemeinhartRALiTBiodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug deliveryJ Control Release20131721122123920039
   PubMed Web of Science ®Google Scholar
• ZhaoRHollisCPZhangHSunLGemeinhartRALiTHybrid nanocrystals: achieving concurrent therapeutic and bioimaging functionalities toward solid tumorsMol Pharm2011851985199121812439
   PubMedGoogle Scholar
• BankerGSSiepmannJRhodesCModern PharmaceuticsBoca RatonMarcel Dekker Press2002
   Google Scholar
• TorchilinVTumor delivery of macromolecular drugs based on the EPR effectAdv Drug Deliv Rev201163313113520304019
   PubMed Web of Science ®Google Scholar
• FengLXLiMLiuYJYangSMZhangNSynergistic enhancement of cancer therapy using a combination of ceramide and docetaxelInt J Mol Sci20141534201422024619193
   PubMed Web of Science ®Google Scholar
• XiaoYLiuYYangSSorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatmentColloid Surf B20161418392
   PubMed Web of Science ®Google Scholar